TrialBMJ open2016

Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.

Nestor A Molfino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.